As for spontaneous leukaemias, immunized BALB/c mice showed an increased incidence over the controls, while in Fl (Swiss x AKR) mice the incidence was similar but the latent period was shorter. Furthermore, in long-term observations the MSV-M-immunized mice showed an increased mortality, which could be related to (1) new phenotypic mixtures between MSV-M and leukaemia viruses; (2) reactivation of MSV-M sarcoma-genesis with age, and (3) genotype susceptibility to MSV-M.
However, on different occasions, active immunization methods have been used, such as: (1) syngeneic transplantable leukaemia in sub-threshold doses (Axelrad, 1963; Klein & Klein, 1964; Pasternak & Graffi, 1963) ; (2) allogeneic transplantable leukaemia (Klein & Klein, 1964; McCoy et al., 1967; Pasternak & Graffi, 1963) ; (3) culture cells chronically infected with virus (Barski & Youn, 1965; Mayyasi et al., 1968) ; (4) infectious leukaemia virus (Bianco et al., 1966; Glynn et al., 1964 Glynn et al., , 1968 Klein & Klein, 1964; Mayyasi & Moloney, 1967; McCoy et al., 1967; Sachs, 1962; Slettenmark & Klein, 1962) ; (5) attenuated leukaemia virus (Fink & Rauscher, 1964; Friend, 1959; Huebner et al., 1976; Kelloff et al., 1976; Mayyasi & Moloney, 1967; McCoy et al., 1967; Tyndall, et al., 1967) ; (6) infectious murine sarcoma virus Huebner et al., 1976; Basombrio et al., 1977) ; and (7) purified viral components (Hunsmann et al., 1975; Ihle et al., 1976a,b) . The variability among experimental protocols makes a direct comparison of the different results extremely difficult.
The Moloney sarcoma virus system (MSV-M) has been well characterized (Harvey & East, 1971) . Its tissue tropism is different from that of leukaemic viruses, since it replicates preferentially in muscle and not in haemopoietic tissue (Perk & Maloney, 1966) and induces atypical granulomas (Simons & McCully, 1970) . The tumours induced by MSV-M in normal adult mice regress after attaining considerable size, leaving the animals free of disease (Fefer, 1968) . Immunologically, MSV-M has been studied extensively; both the humoral and the cellular immune responses (Lamon et al., 1974) have been characterized. It has also been observed that MSV-M shares antigens with the Friend-Moloney-Rauscher complex ; its neutralization with rat anti-Gross serum (Fefer, 1967) opened up the possibility of using this virus for vaccination against Gross leukaemias.
On the basis of the accumulated data, MSV-M seems to be the best characterized of all murine oncorna viral systems. Therefore, the purpose of this study was to use a unique standardized protocol with MSV-M as a live viral vaccine for the prevention of primary, transplanted and spontaneous leukaemia in the mouse. Precerutti-Law leukaemia virus (PLLV/ T2) was introduced to our laboratory by Dr Precerutti 10 years ago as a BALB leukaemia of short latency, propagated by acellular extracts (Precerutti & Law, 1963) . H179A leukaemia virus (H179A LV) was obtained from acellular extracts of leukaemia that appeared in a female BALB/c mouse, 2 months of age, 17 days after it had been inoculated with AKR leukaemic material (Pasqualini et al., 1968) .
Transplantable leukaemias.-Different leukaemias have been induced in our laboratory in the course of 20 years; many are maintained by serial cell passage (Pasqualini et al., 1968) of which the following were studied:
HlIO Leukaemia, obtained from a 3 month old BALB female, 37 days after being inoculated with human material via the intrasplenic route; R14 leukaemia, obtained from a 10-month-old BALB/c female mouse that had received 3 weekly doses of 150 rad; P277 leukaemia, obtained from mice inoculated with Moloney leukaemia virus.
Spontaneous leukaemias.-High-and lowleukaemia strains were needed for the experiments. (AKR x Swiss) Fl hybrids were used as a high-leukaemia strain, since they proved to have a 30% incidence of leukemia at an average age of 12 months. The BALB/c strain was selected as a low-leukaemia strain, having a 15% spontaneous incidence at an average age of 18 months, in our laboratory.
Preparation and titration of Moloney sarcoma virus vaccine.-MSV-M used in the experiments originated from lot SVR-P166 kindly forwarded by Dr. K. E. Hellstrom, University of Washington, Seattle, U.S.A. A large number of newborn BALB/c mice were inoculated. Subcutaneous sarcomas originating from this inoculum were disrupted in 10 volumes of cold phosphate-buffer saline plus streptomycin and penicillin (PBS) and then homogenized in a Virtis blender Model S23. The homogenate was centrifuged twice at 5000 and 10,000 revs/min for 15 and 20 min respectively. Supernatants were then transferred to glass ampoules, sealed and frozen at -196°C for storage.
The titre of MSV-M was calculated in vivo using the Reed-Muench method, estimating take doses at Day 35. 0-2 ml of 10-fold dilutions of MSV-M stock were inoculated i.m. into 2-month-old BALB/c and Swiss mice.
Stock MSV-M, used in all experiments, contained 1P5 x 10J Take-dose 50/ml.
Preparation and titration of murine leukaemia virus.-Leukaemic tissues (spleen and lymph nodes) were disrupted in 10 volumes of PBS with a glass homogenizer and processed in the same manner as for MSV-M sarcomas. Murine leukaemia viruses used to challenge MSV-M immunized mice were titrated in vivo in 2-3-month-old BALB/c mice. Tenfold dilutions of stored stock viruses were inoculated i.p., each mouse receiving 0-1 ml, and the proportion of mice dying with leukaemia within 3 months was recorded. The titre of the murine leukaemia viruses used was calculated by the Reed-Muench method estimating lethal doses at the day indicated between brackets in each case. Titres were: RLV: 3-7x102 LD50 (69)/ml; FLV: 5x102 LD50 (74)/ml; PLLV-T2LV: 51 x 103 LD50 (66)/ml and H179ALV: 5 x 104 LD50 (56) The experimental protocol for immunoprevention studies.-In order to test the live MSV-M immunogen, mice were subjected to a standardized protocol: inoculation of 0-2 ml MSV-M s.c. which induced localized sarcomas which quickly regressed, followed by a booster immunization 30-40 days later. The control group received 0-2 ml of a supernatant of normal BALB/c muscle extracts. Challenge of the MSV-M immunized mice with either leukaemia virus or cells was accomplished 30 days after the booster immunization, when mice were 4 months old. The incidence of primary and transplanted leukaemia in experimental and control mice was carefully recorded. All sick animals with evident splenomegaly were sacrified and autopsied: presence of enlarged spleen, thymus or lymph nodes indicated leukaemia.
The data were evaluated by the x2 and Mann-Whitney U tests.
RESULTS

Characterization of MS V-M stock
Tumour incidence, tumour growth, survival rate and immunological status were studied using different dilutions of MSV-M stock inoculated either i.m. or s.c. By s.c. route, tumour incidence (Table I) and growth ( Fig. 1) were greatly reduced, tumour regression was complete in all animals and the survival rate was considerably greater (Table I) . MSV-M challenge of the immunized survivors showed that the s.c. route immunized as well as the i.m. one, even though 3 months had elapsed since tumour regression (Table II) . These data indicated clearly that with our MSV-M stock the s.c. route of immunization was the better of the two.
Immunoprevention of primary miurine leukaemias
Immunization against Moloney leukaemia.-Since the susceptibility to MLV decreased with age, adult BALB/c mice developed a moderate splenomegaly which progressed slowly, with many mice surviving beyond 1 year, so that immunity was evaluated by recording the inhibition of leukaemic splenomegaly (Basombrio et al., 1977) .
A group of 15 MSV-M-immunized BALB/c mice received 0 5 ml of MLV i.p., (Fig. 3) . 14/17 (82%) of MSV-M immunized mice surviving against 4/21 (19%) of the controls (P < 0'00 1). Further observation showed that mortality progressively increased in both groups, only 4/17 (23%) of the MSV-M immunized mice and 2/21 (90) of the controls surviving at 369 days.
Immunization against Friend leukaemia.
A group of 21 MSV-M-immunized
BALB/c mice, together with 23 controls, were challenged with FLV, each mouse receiving 0 2 ml of a 1/500 dilution of FLV stock. The survival rate was similar in both groups after 169 days of observation (7/21 immunized and 7/23 controls). As shown in Table III Immunization against Gross leukaemia. -A group of 20 MSV-M-immunized Swiss mice, together with 22 controls, were challenged i.p. with 0-2 ml of a GLV supernatant. After 296 days, 9/20 (45%) immunized and 7/22 (31%) of control mice had survived (Fig. 6) inoculation. An analysis of leukaemia incidence (Table IV) showed that 4 confirmed and 14 presumptive leukaemias appeared in the immunized group and only 1 in the controls. This protocol actually increased the incidence of spontaneous leukaemia in BALB/c mice. Effect in (Swiss x AKR) F1 mice. (Swiss x AKR) F1 mice presented a 350o incidence of spontaneous leukaemia in an average of 18 months. In this experiment only one inoculation of MSV-M was used to immunize the mice, in order to reduce 
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dence of leukaemia in both MSV-Mimmunized (10/42, 23%) and control (11/47, 27°,) groups was similar, the leukaemias appearing in the MSV-Mimmunized mice up to 13 months of age had shorter latency than those seen in the controls (P < 0.02) (Fig. 11) . Thus this protocol did not prevent spontaneous leukaemogenesis in (Swiss x AKR) F1 hybrids, but rather accelerated the onset of leukaemia.
DISCUSSION
Because of the different biological behaviour of MSV-M strains (Lavrin et al., 1973) our studies began with an immunological and virological characterization of the MSV-M viral strain to be used. The s.c. route of inoculation was chosen because it induced smaller tumours which regressed more rapidly, so that survival was greater, though the immunity induced was as strong as with the i.m. route.
Moreover, the long-term pathogenicity responsible for recurrences of sarcoma in sites different from the first inoculation (diaphragm, spleen, liver) was also significantly reduced. The explanation may be that in the s.c. region there is less muscular tissue available for the replication of the virus with special tropism for this tissue. The effectiveness of the experimental protocol using MSV-M as a live vaccine for immunoprevention studies was confirmed in the first group of experiments in which immunized mice were challenged with FLV, RLV7 and MLV, also used in other laboratories for immunoprevention assays. Extension of the experiments to other leukaemia viruses originating in our laboratory showed effective protection against primary leukaemias induced by PLLV and HI 79A/LV. However, although serological data (Fefer, 1967) and in immunization with MSV-G (Basombrio et al., 1977) it has been observed that after regression of MSV-M-induced sarcomas the virus remains in the lymphoid tissues of the mouse as a persistent infection controlled by the host (Chieco-Bianchi & Collavo, 1976; Giuliani et al., 1973) . On the other hand, 6-month-old mice show again a great sensitivity to MSV-M oncogenesis (Pazmifio & Yuhas, 1973) . Thus renewed MSV-M sarcomagenesis might cause unexpected mortality in long-term experiments due to reactivation of the virus. Thirdly, the genotype of mice has a great bearing on the result of MSV-M oncogenesis: BALB/c mice are known to be very susceptible, whilst (Swiss x AKR) F1 hybrids are very resistant which could account for the observed difference in mortality.
Could inactivation of the immunizing MSV-M virus override these difficulties? Probably not, since recent observations have shown that the protein fraction gp7l from FLV inoculated in C57 and AKR mice produces viral activation (Ihle et al., 1976a) . This would suggest a mechanism mediated by viral components, an effect capable of complicating any study on the viral immunoprevention of murinie leukaemia. The blocking of viral replication would not be a sufficient guarantee to hinder the activation of endogenous virus which would lead to leukaemic transformation in mice subjected to long observation.
Recapitulating, our protocol, using a live MSV-M vaccine, proved successful in short-term experiments, protecting against the induction of primary leukaemias and partially against transplantable leukaemias. It was not possible, however, to obtain protection against spontaneous leukaemias.
